Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab and Cemdisiran Combination Therapy in PNH
NCT07154745Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- Jan 2030
- Modality
- Antisense DNA, Recombinant Proteins and Enzymes, Conjugated siRNA
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of pozelimab and cemdisiran in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percent change in Lactate Dehydrogenase at 28 weeks. Started Jun 2026; status: recruiting.
02
Drugs
pozelimabcemdisiran
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT07154745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07154745.